Areerak Phanphaisarn

Areerak Phanphaisarn

Auto-generated profile, based on publicly available information

Areerak Phanphaisarn

Department of Orthopaedics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SOSanthasiri Orrapin
Santhasiri Orrapin
SUSasimol Udomruk
Sasimol Udomruk
WLWorakitti Lapisatepun
Worakitti Lapisatepun
SMsutpirat moonmuang
sutpirat moonmuang
APAreerak Phanphaisarn
Areerak Phanphaisarn
PCParunya Chaiyawat
Parunya Chaiyawat
Circulating tumor cells (CTCs) play a key role in hematogenous metastasis and post-surgery recurrence. In hepatocellular carcinoma (HCC), CTCs have emerged as a valuable source of therapeutically relevant information. Certain subsets or phenotypes of CTCs can survive in the bloodstream and induce metastasis. Here, we performed a systematic review on the importance of epithelial–mesenchymal transition (EMT)-CTCs and circulating cancer stem cells (CCSCs) in metastatic processes and their prognostic power in HCC management. PubMed, Scopus, and Embase databases were searched for relevant publications. PRISMA criteria were used to review all studies. Twenty publications were eligible, of which 14, 5, and 1 study reported EMT-CTCs, CCSCs, and both phenotypes, respectively. Most studies evaluated that mesenchymal CTCs and CCSCs positivity were statistically associated with extensive clinicopathological features, including larger size and multiple numbers of tumors, advanced stages, micro/macrovascular invasion, and metastatic/recurrent disease. A preliminary meta-analysis showed that the presence of mesenchymal CTCs in pre- and postoperative blood significantly increased the risk of early recurrence. Mesenchymal-CTCs positivity was the most reported association with inferior outcomes based on the prognosis of HCC recurrence. Our finding could be a step forward, conveying additional prognostic values of CTC subtypes as promising biomarkers in HCC management.

14 October 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
JKJeerawan Klangjorhor
Jeerawan Klangjorhor
PCParunya Chaiyawat
Parunya Chaiyawat
PTPimpisa Teeyakasem
Pimpisa Teeyakasem
NSNutnicha Sirikaew
Nutnicha Sirikaew
APAreerak Phanphaisarn
Areerak Phanphaisarn
DPDumnoensun Pruksakorn
Dumnoensun Pruksakorn

25 January 2018 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
PAPichitchai Atthakomol
Pichitchai Atthakomol
WMWorapaka Manosroi
Worapaka Manosroi
APAreerak Phanphaisarn
Areerak Phanphaisarn
SPSureeporn Phrompaet
Sureeporn Phrompaet
SISawan Iammatavee
Sawan Iammatavee
STSiam Tongprasert
Siam Tongprasert
Recent studies have reported that radial extracorporeal shock wave therapy (rESWT) reduces pain and improves function in patients with mild to moderately severe carpal tunnel syndrome (CTS) compared to a placebo. However, most of those studies used multi-session rESWT combined with wrist support and evaluation of efficacy was limited to a maximum of 14 weeks. The prospective randomized controlled trial compared efficacy in relieving pain and improving clinical function between single-dose rESWT and local corticosteroid injection (LCsI) over the mid-term (24 weeks). Twenty-five patients with mild to moderately severe CTS were randomized to receive either single-dose rESWT (n = 13) or LCsI (n = 12). Primary outcomes were evaluated using the Boston self-assessment questionnaire (BQ), while secondary outcomes used the Visual analogue scale (VAS) and electrodiagnostic parameters. Evaluations at baseline and at 1, 4, 12 and 24 weeks after treatment were performed. There was significantly greater improvement in symptom severity scores, functional scores and Boston questionnaire scores at weeks 12 to 24 in the rESWT group compared to the LCsI group. When compared to the baseline, there was significant reduction of VAS and functional score in the rESWT group at weeks 12 and 24. The LCsI group had no statistically significant differences in VAS reduction and functional score of the same period. Treatment of CTS using single-dose rESWT has a carry-over effect lasting up to 24 weeks suggesting that single-dose rESWT is appropriate for treatment of mild to moderate CTS and provides longer-lasting benefits than LCsI. ( TCTR20150709001 ). Registered 9 July 2015

1 December 2015 in Cancer Epidemiology
Verified
Journal Article
Closed access
DPDumnoensun Pruksakorn
Dumnoensun Pruksakorn
APAreerak Phanphaisarn
Areerak Phanphaisarn
OAOlarn Arpornchayanon
Olarn Arpornchayanon
NUNantawat Uttamo
Nantawat Uttamo
TLTaninnit Leerapun
Taninnit Leerapun
JSJongkolnee Settakorn
Jongkolnee Settakorn

1 February 2018 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
PCParunya Chaiyawat
Parunya Chaiyawat
DPDumnoensun Pruksakorn
Dumnoensun Pruksakorn
APAreerak Phanphaisarn
Areerak Phanphaisarn
PTPimpisa Teeyakasem
Pimpisa Teeyakasem
JKJeerawan Klangjorhor
Jeerawan Klangjorhor
JSJongkolnee Settakorn
Jongkolnee Settakorn
Epigenetic aberrations are recognized as having pivotal roles in cancer etiology and progression. Histone deacetylases are among the most studied epigenetic modulators in various cancer types. The expression levels of class I histone deacetylase isoforms 1, 2, and 3 in patient-derived primary osteosarcoma cells (6 cases) was investigated, comparing them to normal bone graft-derived osteoblasts (6 cases) using the immunoblotting technique. Expression profiles of histone deacetylases in high-grade osteosarcoma tissue of 89 patients were examined and their association with clinicopathologic parameters and the patient survival was evaluated. Histone deacetylases were immunohistochemically stained on formalin-fixed paraffin-embedded biopsied tissue. Primary osteosarcoma cells expressed higher levels of histone deacetylase 1 and histone deacetylase 2, but lower levels of histone deacetylase 3 compared to benign osteoblasts. Overall, 82, 99, and 93% of 89 osteosarcomas showed nuclear expression of the histone deacetylase isoforms 1, 2, and 3, respectively. Low levels of histone deacetylase 1 were significantly associated with a high Enneking stage (P=0.014) and the presence of initial metastasis (P=0.040), while low levels of histone deacetylase 3 were significantly correlated with age >15 years (P=0.026). Univariate survival analysis found significantly shorter survival in the patients with a high Enneking stage (P<0.001), axial location (P=0.009), presence of initial metastasis (P<0.001), low-histone deacetylase 1 expression (P=0.038), and low-all-histone deacetylases expression (P=0.016). Multivariate survival analysis showed that only axial location (P=0.011) and low-all-histone deacetylases expression (P=0.039) were independent prognostic factors. In subgroup analysis of stage IIB patients (n=45), only axial location and low-all-histone deacetylases expression were associated with shorter survival in both univariate and multivariate analysis (axial location, P=0.008 and 0.010; low-all-HDACs, P=0.013 and 0.038, respectively). Low levels of all-histone deacetylases expression were significantly associated with advanced disease status and short survival. These findings may be a guide to future use of histone deacetylase inhibitors in osteosarcoma patients.

1 March 2018 in Journal of Bone Oncology
Verified
Journal Article
Open access
DPDumnoensun Pruksakorn
Dumnoensun Pruksakorn
APAreerak Phanphaisarn
Areerak Phanphaisarn
JSJongkolnee Settakorn
Jongkolnee Settakorn
UAUrarat Arpornchayanon
Urarat Arpornchayanon
Apichat TantraworasinApichat Tantraworasin
Apichat Tantraworasin
PTPimpisa Teeyakasem
Pimpisa Teeyakasem
Background: This study identifies the overall survival status of lung cancer patients with bone metastasis and metastasis patterns. Poor prognostic factors were identified to develop a scoring system for estimating survival period after bone metastasis. Methods: A retrospective cohort analysis was performed at Chiang Mai University for the period January 1, 2006 and December 31, 2013. Time-to-event analysis was performed to estimate survival rate. The primary end point was death related to lung cancer. Univariate and multivariate analysis of the prognostic variables was done using the Cox's regression model. The score was derived from the corresponding estimated regression coefficients of significantly poor prognostic factors. Results: A total of 505 lung cancer with bone metastasis patients were analyzed. Four hundred two cases (79.6%) were concurrent diagnosis and 103 (20.4%) were subsequent diagnosis. The median survival time of lung cancer after bone metastasis 148 days. Male gender and ECOG 3-4 were significant poor prognostic factors for lung cancer after bone metastasis, with hazard ratios of 1.42 (95% CI 1.17-1.73), and 1.30 (95% CI 1.06-1.60), respectively. Prognosis score was determined using the binary term present/not-present for those factors. The curve from prognostic score summations of 2, 1 and 0 presented a good discrimination of survival expectancy, showing an expected median survival time of approximately 109, 146, and 225 days, respectively. Conclusions: Prognostic score is a clinically simple and easy method for estimating life expectancy and for guiding interventions in bone metastasis of lung cancer.